Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Needham重申對apellis pharmaceuticals的買入評級，維持目標價85美元。
Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.
Needham分析師Joseph Stringer重申買入Apellis Pharmaceuticals (納斯達克:apellis pharmaceuticals)，並維持85美元的目標價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。